首页 > 最新文献

Hellenic Journal of Cardiology最新文献

英文 中文
Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center 希腊转甲状腺素淀粉样变性心肌病:来自国家转诊中心的临床见解。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2023.09.019

Background

Clinical characteristics and outcomes of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) vary by region, necessitating the acquisition of country-specific evidence for proper management.

Methods

This is an observational study including sequential patients presenting in the Amyloidosis Reference Center of Greece, from 01/2014 to 12/2022. ATTR-CM was diagnosed by positive scintigraphy and exclusion of light-chain amyloidosis or positive biopsy typing. Genetic testing was performed in all cases.

Results

In total, 109 ATTR-CM patients were included (median age, 81 years) of which 15 carried TTR mutations (27% Val30Met). Most patients (82%) presented with heart failure and 59% with atrial fibrillation, while 10% had aortic stenosis. Importantly, 78 (71.6%) had clinically significant extracardiac manifestations (45% musculoskeletal disorder, 40% peripheral neuropathy, and 33% gastrointestinal symptoms). Sixty-five (60%) received disease-specific treatment with tafamidis. Estimated median survival was 48 months; advanced NYHA class, National Amyloidosis Center stage, eGFR<45 ml/kg/1.73 m2, NT-pro-BNP>5000 pg/mL were associated with worse survival, while tafamidis treatment was associated with improved survival in patients with IVS≥ 12 mm.

Discussion

These are the first data describing the characteristics, management, and outcomes of patients with ATTR-CM in Greece, which could influence local guidelines.

背景:转甲状腺素淀粉样变性心肌病(ATTR-CM)患者的临床特征和结果因地区而异,因此需要获得国家特定的证据进行适当的治疗。方法:这是一项观察性研究,包括2014年1月至2022年12月在希腊淀粉样变性参考中心就诊的连续患者。ATTR-CM是通过阳性闪烁扫描和排除轻链淀粉样变性或阳性活检分型诊断的。所有病例均进行了基因检测。结果:包括109名ATTR-CM患者(中位年龄81岁),其中15人携带TTR突变(27%的Val30Met)。大多数患者(82%)出现心力衰竭,59%出现心房颤动,10%出现主动脉狭窄。重要的是,78例(71.6%)有临床意义的心外表现(45%为肌肉骨骼疾病,40%为周围神经病变,33%为胃肠道症状)。六十五名(60%)患者接受了针对疾病的tafamidis治疗。估计中位生存期为48个月;晚期NYHA分级、国家淀粉样变性中心分期、eGFR2、NT-pro-BBNP>5000pg/mL与IVS≥12mm患者的生存率提高相关。讨论:这些是描述希腊ATTR-CM患者特征、管理和结果的第一批数据,可能会影响当地指南。简称:希腊的转甲状腺素心肌病。
{"title":"Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center","authors":"","doi":"10.1016/j.hjc.2023.09.019","DOIUrl":"10.1016/j.hjc.2023.09.019","url":null,"abstract":"<div><h3>Background</h3><p>Clinical characteristics and outcomes of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) vary by region, necessitating the acquisition of country-specific evidence for proper management.</p></div><div><h3>Methods</h3><p>This is an observational study including sequential patients presenting in the Amyloidosis Reference Center of Greece, from 01/2014 to 12/2022. ATTR-CM was diagnosed by positive scintigraphy and exclusion of light-chain amyloidosis or positive biopsy typing. Genetic testing was performed in all cases.</p></div><div><h3>Results</h3><p>In total, 109 ATTR-CM patients were included (median age, 81 years) of which 15 carried <em>TTR</em> mutations (27% Val30Met). Most patients (82%) presented with heart failure and 59% with atrial fibrillation, while 10% had aortic stenosis. Importantly, 78 (71.6%) had clinically significant extracardiac manifestations (45% musculoskeletal disorder, 40% peripheral neuropathy, and 33% gastrointestinal symptoms). Sixty-five (60%) received disease-specific treatment with tafamidis. Estimated median survival was 48 months; advanced NYHA class, National Amyloidosis Center stage, eGFR&lt;45 ml/kg/1.73 m<sup>2</sup>, NT-pro-BNP&gt;5000 pg/mL were associated with worse survival, while tafamidis treatment was associated with improved survival in patients with IVS≥ 12 mm.</p></div><div><h3>Discussion</h3><p>These are the first data describing the characteristics, management, and outcomes of patients with ATTR-CM in Greece, which could influence local guidelines.</p></div>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966623001902/pdfft?md5=3a3da55ff2cbab019ccb1dba4a84b69c&pid=1-s2.0-S1109966623001902-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BEAT-IT: A de-novo cardiac screening programme in Maltese adolescents BEAT-IT:一项针对马耳他青少年的全新心脏筛查计划。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2023.09.012

Aims

Sudden cardiac death (SCD) in young individuals is often unexpected, provoking substantial emotional stress for family and friends of the deceased. Cardiac screening may identify individuals who harbour disorders linked to SCD. The feasibility and diagnostic yield of a nationwide cardiac screening programme in adolescents has never been explored.

Methods

All individuals eligible for cardiac screening (students aged 15 years) were systematically invited to enrol. Students were provided with a health questionnaire. ECGs were acquired at school. A physician led consultation was carried out on site. Participants with an abnormal screen were then referred for secondary evaluation to the nation’s tertiary centre. Feasibility criteria included a) participation rate >60%, b) adherence to secondary evaluation >80%, and c) cost per individual screened equating to <€100. The diagnostic yield was also evaluated.

Results

At the end of enrolment, 2708 students gave consent (mean 15 years, 50.4% male), equating to 67.9% of the eligible cohort. Overall, 109 participants (4.0%) were referred for further evaluation. An abnormal electrocardiogram (ECG) was the most common reason for referral (3.7%). Fifteen individuals (0.6%) were diagnosed with a cardiac condition. Nine (0.3%) had a condition linked to SCD (n = 1 Long-QT syndrome, n = 1 Hypertrophic Cardiomyopathy, n = 5 Wolff-Parkinson White, n = 2 coronary anomalies). The yield was similar in athletes and non-athletes (p = 0.324). The cost per cardiac individual screened equated to €51.15.

Conclusion

A nationwide systematic cardiac screening programme for adolescent athletes and non-athletes is feasible and cost-efficient, provided that responsible centres have the appropriate infrastructure.

目的:年轻人的心脏性猝死(SCD)通常是出乎意料的,会给死者的家人和朋友带来巨大的情感压力。心脏筛查可以识别患有SCD相关疾病的个体。全国青少年心脏筛查项目的可行性和诊断效果从未被探索过。方法:系统地邀请所有符合心脏筛查条件的个体(15岁的学生)参加。向学生提供了一份健康问卷。心电图是在学校获得的。现场进行了医生主导的会诊。筛查异常的参与者随后被转介到国家高等教育中心进行二次评估。可行性标准包括a)参与率>60%,b)二次评估的依从性>80%,以及c)每个筛选个体的成本,相当于结果:在入学结束时,2708名学生表示同意(平均15岁,50.4%为男性),相当于合格队列的67.9%。109名参与者(4.0%)被转介进行进一步评估。心电图异常是转诊的最常见原因(3.7%)。15人(0.6%)被诊断为心脏病。9人(0.3%)患有与SCD相关的疾病(n=1 LQTS,n=1 HCM,n=5 WPW,n=2冠状动脉异常)。运动员和非运动员的产量相似(p=0.324)。每个心脏筛查个体的成本相当于51.15欧元。
{"title":"BEAT-IT: A de-novo cardiac screening programme in Maltese adolescents","authors":"","doi":"10.1016/j.hjc.2023.09.012","DOIUrl":"10.1016/j.hjc.2023.09.012","url":null,"abstract":"<div><h3>Aims</h3><p>Sudden cardiac death (SCD) in young individuals is often unexpected, provoking substantial emotional stress for family and friends of the deceased. Cardiac screening may identify individuals who harbour disorders linked to SCD. The feasibility and diagnostic yield of a nationwide cardiac screening programme in adolescents has never been explored.</p></div><div><h3>Methods</h3><p>All individuals eligible for cardiac screening (students aged 15 years) were systematically invited to enrol. Students were provided with a health questionnaire. ECGs were acquired at school. A physician led consultation was carried out on site. Participants with an abnormal screen were then referred for secondary evaluation to the nation’s tertiary centre. Feasibility criteria included a) participation rate &gt;60%, b) adherence to secondary evaluation &gt;80%, and c) cost per individual screened equating to &lt;€100. The diagnostic yield was also evaluated.</p></div><div><h3>Results</h3><p>At the end of enrolment, 2708 students gave consent (mean 15 years, 50.4% male), equating to 67.9% of the eligible cohort. Overall, 109 participants (4.0%) were referred for further evaluation. An abnormal electrocardiogram (ECG) was the most common reason for referral (3.7%). Fifteen individuals (0.6%) were diagnosed with a cardiac condition. Nine (0.3%) had a condition linked to SCD (n = 1 Long-QT syndrome, n = 1 Hypertrophic Cardiomyopathy, n = 5 Wolff-Parkinson White, n = 2 coronary anomalies). The yield was similar in athletes and non-athletes (p = 0.324). The cost per cardiac individual screened equated to €51.15.</p></div><div><h3>Conclusion</h3><p>A nationwide systematic cardiac screening programme for adolescent athletes and non-athletes is feasible and cost-efficient, provided that responsible centres have the appropriate infrastructure.</p></div>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966623001835/pdfft?md5=009f3bc36731352127b11180f39b6d43&pid=1-s2.0-S1109966623001835-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41121368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention β1-阻断剂在降低急性冠状动脉综合征或经皮冠状动脉介入治疗后采用强效双重抗血小板治疗的患者出血风险中的作用。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2023.09.017

Background

β1-blockers could improve clinical outcomes in patients with coronary artery disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover, recent studies have suggested that β1-blockers may also have the potential to reduce bleeding risk.

Objectives

This study aimed to evaluate the association between β1-blockers and bleeding risk in the patients prescribed with potent dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI).

Methods

Patients with ACS or undergoing PCI treated by DAPT of ticagrelor and aspirin were consecutively recruited. Follow-up for all eligible patients was conducted for 1 year. Major bleeding outcomes were defined as events that were type ≥2 based on the Bleeding Academic Research Consortium (BARC) criteria.

Results

A total of 1,113 eligible ticagrelor-treated patients were recruited. During the 1-year follow-up interval, 142 (12.6%) patients experienced BARC ≥2 bleedings including 23 patients (2.1%) suffering BARC ≥3 bleedings, with the most common site of bleeding located in the gastrointestinal tract. β1-blockers treatment was associated with a lower risk of BARC ≥2 bleedings (11.2% vs. 23.3%, adjusted HR: 0.42, 95% CI: 0.28-0.62, P < 0.01). Moreover, metoprolol (11.1% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.37-0.83, P < 0.01) and bisoprolol (11.3% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.33-0.96, P = 0.04) had similar effects on the reduction of bleeding risk.

Conclusion

β1-blockers might be beneficial for the reduction of bleeding risk in potent dual antiplatelet therapy patients with ACS or undergoing PCI.

背景:β1-阻断剂可通过降低心率、血压和心肌收缩力来改善冠心病患者的临床疗效。此外,最近的研究表明,β1-阻断剂也有可能降低出血风险。目的:本研究旨在评估急性冠状动脉综合征(ACS)或经皮冠状动脉介入治疗(PCI)后接受强效双抗血小板治疗(DAPT)的患者的β1-激酶与出血风险之间的关系。对所有符合条件的患者进行了1年的随访。根据出血学术研究联合会(BARC)标准,主要出血结果被定义为≥2型的事件。结果:共招募了1113名符合条件的替卡格雷治疗患者。在1年的随访期间,142名(12.6%)患者出现BARC≥2次出血,其中23名(2.1%)患者出现了BARC≥3次出血,最常见的出血部位位于胃肠道。β1-阻断剂治疗可降低BARC≥2次出血的风险(11.2%vs.23.3%,调整后HR:0.42,95%CI:0.28-0.62,P<0.01)。此外,美托洛尔(11.1%vs.23.3%,调整后HR:0.56,95%CI:0.37-0.83,P<0.01)和比索洛尔(11.3%vs.233%,调整前HR:0.56,95%CI:0.33-0.96,P=0.04)在降低出血风险方面具有相似的效果。结论:β1-阻断剂可能有助于降低ACS或PCI双重抗血小板治疗患者的出血风险。
{"title":"β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention","authors":"","doi":"10.1016/j.hjc.2023.09.017","DOIUrl":"10.1016/j.hjc.2023.09.017","url":null,"abstract":"<div><h3>Background</h3><p>β1-blockers could improve clinical outcomes in patients with coronary artery disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover, recent studies have suggested that β1-blockers may also have the potential to reduce bleeding risk.</p></div><div><h3>Objectives</h3><p>This study aimed to evaluate the association between β1-blockers and bleeding risk in the patients prescribed with potent dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI).</p></div><div><h3>Methods</h3><p>Patients with ACS or undergoing PCI treated by DAPT of ticagrelor and aspirin were consecutively recruited. Follow-up for all eligible patients was conducted for 1 year. Major bleeding outcomes were defined as events that were type ≥2 based on the Bleeding Academic Research Consortium (BARC) criteria.</p></div><div><h3>Results</h3><p>A total of 1,113 eligible ticagrelor-treated patients were recruited. During the 1-year follow-up interval, 142 (12.6%) patients experienced BARC ≥2 bleedings including 23 patients (2.1%) suffering BARC ≥3 bleedings, with the most common site of bleeding located in the gastrointestinal tract. β1-blockers treatment was associated with a lower risk of BARC ≥2 bleedings (11.2% vs. 23.3%, adjusted HR: 0.42, 95% CI: 0.28-0.62, P &lt; 0.01). Moreover, metoprolol (11.1% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.37-0.83, P &lt; 0.01) and bisoprolol (11.3% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.33-0.96, P = 0.04) had similar effects on the reduction of bleeding risk.</p></div><div><h3>Conclusion</h3><p>β1-blockers might be beneficial for the reduction of bleeding risk in potent dual antiplatelet therapy patients with ACS or undergoing PCI.</p></div>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966623001884/pdfft?md5=e72e7b457e71d814b3af94e351f326fb&pid=1-s2.0-S1109966623001884-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of 10-year cardiovascular disease risk by diabetes status and lipoprotein-a levels; the HellenicSCORE II+ 通过糖尿病状态和脂蛋白-a水平预测10年心血管疾病风险;希腊SCORE II。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2023.10.001

Background

The aim of this study was to develop an updated model to predict 10-year cardiovascular disease (CVD) risk for Greek adults, i.e., the HellenicSCORE II+, based on smoking, systolic blood pressure (SBP), total and high-density-lipoprotein (HDL) cholesterol levels, and stratified by age group, sex, history of diabetes, and lipoprotein (Lp)-a levels.

Methods

Individual CVD risk scores were calculated through logit-function models using the beta coefficients derived from SCORE2. The Attica study data were used for the calibration (3,042 participants, aged 45 (14) years; 49.1% men). Discrimination ability of the HellenicSCORE II+ was assessed using C-index (range 0-1), adjusted for competing risks.

Results

The mean HellenicSCORE II+ score was 6.3% (95% confidence interval (CI) 5.9% to 6.6%) for men and 3.7% (95% CI 3.5% to 4.0%) for women (p < 0.001), and were higher compared to the relevant SCORE2; 23.5% of men were classified as low risk, 40.2% as moderate, and 36.3% as high risk, whereas the corresponding percentages for women were 56.2%, 18.6%, and 25.2%. C-statistic index was 0.88 for women and 0.79 for men when the HellenicSCORE II+ was applied to the Attica study data, suggesting very good accuracy. Stratified analysis by Lp(a) levels led to a 4% improvement in correct classification among participants with high Lp(a).

Conclusion

HellenicSCORE II+ values were higher than SCORE2, confirming that the Greek population is at moderate-to-high CVD risk. Stratification by Lp(a) levels may assist in better identifying individuals at high CVD risk.

背景:本研究的目的是根据吸烟、收缩压(SBP)、总胆固醇和高密度脂蛋白(HDL)胆固醇水平,并按年龄组、性别、糖尿病史和脂蛋白(Lp)-a水平进行分层,开发一个更新的模型来预测希腊成年人10年心血管疾病(CVD)风险,即HellenicSCORE II+。方法:使用SCORE2得出的β系数,通过logit函数模型计算个体CVD风险评分。阿提卡研究数据用于校准(3042名参与者,年龄45(14)岁;49.1%的男性)。使用C指数(范围0-1)评估HellenicSCORE II+的辨别能力,并根据竞争风险进行调整。结果:男性的平均HellenicSCORE II+评分为6.3%(95%置信区间(CI)5.9%-6.6%),女性为3.7%(95%可信区间3.5%-4.0%)(P结论:HellenicSCORE II+值高于SCORE2,证实希腊人群处于中度至高度心血管疾病风险。通过Lp(a)水平进行分层可能有助于更好地识别心血管疾病高风险人群。
{"title":"Prediction of 10-year cardiovascular disease risk by diabetes status and lipoprotein-a levels; the HellenicSCORE II+","authors":"","doi":"10.1016/j.hjc.2023.10.001","DOIUrl":"10.1016/j.hjc.2023.10.001","url":null,"abstract":"<div><h3>Background</h3><p>The aim of this study was to develop an updated model to predict 10-year cardiovascular disease (CVD) risk for Greek adults, i.e., the HellenicSCORE II+, based on smoking, systolic blood pressure (SBP), total and high-density-lipoprotein (HDL) cholesterol levels, and stratified by age group, sex, history of diabetes, and lipoprotein (Lp)-a levels.</p></div><div><h3>Methods</h3><p>Individual CVD risk scores were calculated through logit-function models using the beta coefficients derived from SCORE2. The Attica study data were used for the calibration (3,042 participants, aged 45 (14) years; 49.1% men). Discrimination ability of the HellenicSCORE II+ was assessed using C-index (range 0-1), adjusted for competing risks.</p></div><div><h3>Results</h3><p>The mean HellenicSCORE II+ score was 6.3% (95% confidence interval (CI) 5.9% to 6.6%) for men and 3.7% (95% CI 3.5% to 4.0%) for women (p &lt; 0.001), and were higher compared to the relevant SCORE2; 23.5% of men were classified as low risk, 40.2% as moderate, and 36.3% as high risk, whereas the corresponding percentages for women were 56.2%, 18.6%, and 25.2%. C-statistic index was 0.88 for women and 0.79 for men when the HellenicSCORE II+ was applied to the Attica study data, suggesting very good accuracy. Stratified analysis by Lp(a) levels led to a 4% improvement in correct classification among participants with high Lp(a).</p></div><div><h3>Conclusion</h3><p>HellenicSCORE II+ values were higher than SCORE2, confirming that the Greek population is at moderate-to-high CVD risk. Stratification by Lp(a) levels may assist in better identifying individuals at high CVD risk.</p></div>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966623001926/pdfft?md5=5100bdb9cda9aab8be398b0ad545e22e&pid=1-s2.0-S1109966623001926-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation 钠-葡萄糖共转运体 2 抑制剂在预防导管消融术后房颤复发方面的疗效。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2024.03.008
{"title":"Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation","authors":"","doi":"10.1016/j.hjc.2024.03.008","DOIUrl":"10.1016/j.hjc.2024.03.008","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966624000691/pdfft?md5=835320d8c44fd90ac03b171bba4d8674&pid=1-s2.0-S1109966624000691-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical phenotypes and outcomes of patients with left ventricular thrombus: an unsupervised cluster analysis. 左心室血栓患者的临床表型和预后:无监督聚类分析
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1016/j.hjc.2024.08.010
Aloysius S T Leow, Fang Qin Goh, Benjamin Y Q Tan, Jamie S Y Ho, William K F Kong, Roger S Y Foo, Mark Y Y Chan, Leonard L L Yeo, Ping Chai, A Geru, Tiong-Cheng Yeo, Siew Pang Chan, Xin Zhou, Gregory Y H Lip, Ching-Hui Sia

Background: Left ventricular thrombus (LVT) can develop in a diverse group of patients with various underlying causes, resulting in divergent natural histories and trajectories with treatment. Our aim was to use cluster analysis to identify unique clinical profiles among patients with LVT and then compare their clinical characteristics, treatment strategies, and outcomes.

Methods: We conducted a retrospective study involving 472 patients with LVT whose data were extracted from a tertiary center's echocardiography database, from March 2011 to January 2021. We used the TwoStep cluster analysis method, examining 19 variables.

Results: Our analysis of the 472 patients with LVT revealed two distinct patient clusters. Cluster 1, comprising 247 individuals (52.3%), was characterized by younger patients with a lower incidence of traditional cardiovascular risk factors and relatively fewer comorbidities compared with Cluster 2. Most patients had LVT attributed to an underlying ischemic condition, with a larger proportion being due to post-acute myocardial infarction in Cluster 1 (68.8%), and due to ischemic cardiomyopathy in Cluster 2 (57.8%). Notably, patients in Cluster 2 exhibited a reduced likelihood of LVT resolution (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.44-0.77, p < 0.001) and a higher risk of all-cause mortality (HR 2.27, 95% CI 1.43-3.60, p = 0.001). These associations persisted even after adjusting for variables such as anticoagulation treatment, the presence of left ventricular aneurysms, and specific LVT characteristics such as mobility, protrusion, and size.

Conclusion: Through TwoStep cluster analysis, we identified two distinct clinical phenotypes among patients with LVT, each distinguished by unique baseline clinical attributes and varying prognoses.

背景:左心室血栓(LVT)可发生在不同的患者群体中,其潜在病因各不相同,因此自然病史和治疗轨迹也各不相同。我们的目的是利用聚类分析确定 LVT 患者的独特临床特征,然后比较他们的临床特征、治疗策略和结果:我们进行了一项回顾性研究,涉及 472 名左心室颤动患者,研究数据来自一家三级中心的超声心动图数据库,时间跨度为 2011 年 3 月至 2021 年 1 月。我们采用了两步聚类分析法,研究了19个变量:我们对 472 名左心室颤动患者的分析显示出两个不同的患者集群。聚类 1 包括 247 人(52.3%),与聚类 2 相比,聚类 1 的特点是患者较年轻,传统心血管风险因素发生率较低,合并症相对较少。大多数患者的 LVT 都是由潜在的缺血性疾病引起的,群组 1 中因急性心肌梗死后引起 LVT 的比例较大(68.8%),群组 2 中因缺血性心肌病引起 LVT 的比例较大(57.8%)。值得注意的是,群组 2 患者的 LVT 解救可能性降低(HR 0.58,95% CI 0.44 - 0.77,p < 0.001),全因死亡风险升高(HR 2.27,95% CI 1.43 - 3.60,p = 0.001)。即使在调整了抗凝治疗、是否存在左心室动脉瘤以及左心室室间隔缺损的具体特征(如活动度、突出度和大小)等变量后,这些关联仍然存在:通过 TwoStep 聚类分析,我们在左心室畸形患者中发现了两种不同的临床表型,每种表型都有独特的基线临床属性和不同的预后。
{"title":"Clinical phenotypes and outcomes of patients with left ventricular thrombus: an unsupervised cluster analysis.","authors":"Aloysius S T Leow, Fang Qin Goh, Benjamin Y Q Tan, Jamie S Y Ho, William K F Kong, Roger S Y Foo, Mark Y Y Chan, Leonard L L Yeo, Ping Chai, A Geru, Tiong-Cheng Yeo, Siew Pang Chan, Xin Zhou, Gregory Y H Lip, Ching-Hui Sia","doi":"10.1016/j.hjc.2024.08.010","DOIUrl":"10.1016/j.hjc.2024.08.010","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular thrombus (LVT) can develop in a diverse group of patients with various underlying causes, resulting in divergent natural histories and trajectories with treatment. Our aim was to use cluster analysis to identify unique clinical profiles among patients with LVT and then compare their clinical characteristics, treatment strategies, and outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective study involving 472 patients with LVT whose data were extracted from a tertiary center's echocardiography database, from March 2011 to January 2021. We used the TwoStep cluster analysis method, examining 19 variables.</p><p><strong>Results: </strong>Our analysis of the 472 patients with LVT revealed two distinct patient clusters. Cluster 1, comprising 247 individuals (52.3%), was characterized by younger patients with a lower incidence of traditional cardiovascular risk factors and relatively fewer comorbidities compared with Cluster 2. Most patients had LVT attributed to an underlying ischemic condition, with a larger proportion being due to post-acute myocardial infarction in Cluster 1 (68.8%), and due to ischemic cardiomyopathy in Cluster 2 (57.8%). Notably, patients in Cluster 2 exhibited a reduced likelihood of LVT resolution (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.44-0.77, p < 0.001) and a higher risk of all-cause mortality (HR 2.27, 95% CI 1.43-3.60, p = 0.001). These associations persisted even after adjusting for variables such as anticoagulation treatment, the presence of left ventricular aneurysms, and specific LVT characteristics such as mobility, protrusion, and size.</p><p><strong>Conclusion: </strong>Through TwoStep cluster analysis, we identified two distinct clinical phenotypes among patients with LVT, each distinguished by unique baseline clinical attributes and varying prognoses.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection and Classification of electrocardiography using hybrid deep learning models. 使用混合深度学习模型检测和分类心电图。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1016/j.hjc.2024.08.011
Immaculate Joy S, Moorthi M, Senthil Kumar K

Background: Electrocardiography (ECGs) has been a vital tool for cardiovascular disease (CVD) diagnosis, which visually depicts the heart's electrical activity. To enhance automatic classification between normal and diseased ECG, it is essential to extract consistent and qualitative features.

Methods: Precision of ECG classification through hybrid Deep Learning (DL) approach leverages both Convolutional Neural Network (CNN) architecture and Variational Autoencoder (VAE) techniques. By combining these methods, we aim to achieve more accurate and robust ECG interpretation. The method is trained and tested over PTB-XL dataset, which contains 21,799 with 12-lead ECGs from 18,869 patients, each spanning 10 seconds. The classification evaluation of 5 super-classes and 23 sub-classes of CVD, with the proposed CNN-VAE model is compared.

Results: The classification of various CVD had resulted with the highest accuracy of 98.51%, specificity of 98.12%, sensitivity 97.9% and F1-score 97.95%. We have also achieved the minimum false positive and false negative rates as 2.07 and 1.87 respectively during validation. The results are validated upon the annotations given by individual cardiologists, who assigned potentially multiple ECG statements to each record.

Conclusion: When compared to other deep learning methods, our suggested CNN-VAE model performs significantly better in testing phase. This study proposes a new architecture of combining CNN-VAE for CVD classification from ECG data, this can help the clinicians to identify the disease earlier and carry further treatment. The CNN-VAE model can better characterize input signals due to its hybrid architecture.

背景:心电图(ECG)是诊断心血管疾病(CVD)的重要工具,它直观地描述了心脏的电活动。为了加强正常心电图和疾病心电图之间的自动分类,必须提取一致的定性特征:通过混合深度学习(DL)方法,利用卷积神经网络(CNN)架构和变异自动编码器(VAE)技术,提高心电图分类的精确度。通过结合这些方法,我们旨在实现更准确、更稳健的心电图解读。该方法在 PTB-XL 数据集上进行了训练和测试,该数据集包含 21,799 份来自 18,869 名患者的 12 导联心电图,每份心电图的时间跨度为 10 秒。结果显示,采用 CNN-VAE 模型对 5 个超级类别和 23 个子类别的心血管疾病进行了分类评估比较:结果:各种心血管疾病分类的准确率最高,达到 98.51%,特异性为 98.12%,灵敏度为 97.9%,F1 分数为 97.95%。在验证过程中,我们还实现了最低的假阳性率和假阴性率,分别为 2.07 和 1.87。这些结果是根据个别心脏病专家给出的注释验证的,他们为每条记录分配了可能多个心电图语句:与其他深度学习方法相比,我们建议的 CNN-VAE 模型在测试阶段的表现明显更好。本研究提出了一种结合 CNN-VAE 的新架构,用于从心电图数据中对心血管疾病进行分类,这有助于临床医生及早发现疾病并进行进一步治疗。CNN-VAE 模型的混合架构能更好地表征输入信号。
{"title":"Detection and Classification of electrocardiography using hybrid deep learning models.","authors":"Immaculate Joy S, Moorthi M, Senthil Kumar K","doi":"10.1016/j.hjc.2024.08.011","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.08.011","url":null,"abstract":"<p><strong>Background: </strong>Electrocardiography (ECGs) has been a vital tool for cardiovascular disease (CVD) diagnosis, which visually depicts the heart's electrical activity. To enhance automatic classification between normal and diseased ECG, it is essential to extract consistent and qualitative features.</p><p><strong>Methods: </strong>Precision of ECG classification through hybrid Deep Learning (DL) approach leverages both Convolutional Neural Network (CNN) architecture and Variational Autoencoder (VAE) techniques. By combining these methods, we aim to achieve more accurate and robust ECG interpretation. The method is trained and tested over PTB-XL dataset, which contains 21,799 with 12-lead ECGs from 18,869 patients, each spanning 10 seconds. The classification evaluation of 5 super-classes and 23 sub-classes of CVD, with the proposed CNN-VAE model is compared.</p><p><strong>Results: </strong>The classification of various CVD had resulted with the highest accuracy of 98.51%, specificity of 98.12%, sensitivity 97.9% and F1-score 97.95%. We have also achieved the minimum false positive and false negative rates as 2.07 and 1.87 respectively during validation. The results are validated upon the annotations given by individual cardiologists, who assigned potentially multiple ECG statements to each record.</p><p><strong>Conclusion: </strong>When compared to other deep learning methods, our suggested CNN-VAE model performs significantly better in testing phase. This study proposes a new architecture of combining CNN-VAE for CVD classification from ECG data, this can help the clinicians to identify the disease earlier and carry further treatment. The CNN-VAE model can better characterize input signals due to its hybrid architecture.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nationwide mortality trends from 2001 to 2020 in Greece: health policy implications under the scope of aging societies. 希腊 2001 至 2020 年全国死亡率趋势:老龄化社会范围内的卫生政策影响》。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-28 DOI: 10.1016/j.hjc.2024.08.009
Maria Nikolaou, Nikolaos Theodorakis, Georgios Feretzakis, Georgia Vamvakou, Christos Hitas, Sofia Kalantzi, Aikaterini Spyridaki, Anastasios Apostolos, Vassilios S Verykios, Konstantinos Toutouzas

Objective: This nationwide study aims to analyze mortality trends for all individual causes in Greece from 2001 to 2020, with a specific focus on 2020, a year influenced by the COVID-19 pandemic. As Greece is the fastest-aging country in Europe, the study's findings can be generalized to other aging societies, guiding the reevaluation of global health policies.

Methods: Data on the population and the number of deaths were retrieved from the Hellenic Statistical Authority. We calculated age-standardized mortality rates (ASMR) and cause-specific mortality rates by sex in three age groups (0-64, 65-79, and 80+ years) from 2001 to 2020. Proportional mortality rates for 2020 were determined. Statistical analysis used generalized linear models with Python Programming Language.

Results: From 2001 to 2020, the ASMR of cardiovascular diseases (CVD) decreased by 42.7% (p < 0.0001), with declines in most sub-causes, except for hypertensive diseases, which increased by 2.8-fold (p < 0.0001). In 2020, the proportional mortality rates of the three leading causes were 34.9% for CVD, 23.5% for neoplasms, and 9.6% for respiratory diseases (RD). In 2020, CVD were the leading cause of death among individuals aged 80+ years (39.3%), while neoplasms were the leading cause among those aged 0-79 years (37.7%). Among cardiovascular sub-causes, cerebrovascular diseases were predominant in the 80+ year age group (30.3%), while ischemic heart diseases were most prevalent among those aged 0-79 years (up to 60.0%).

Conclusions: The global phenomenon of population aging necessitates a reframing of health policies in our aging societies, focusing on diseases with either a high mortality burden, such as CVD, neoplasms, and RD, or those experiencing increasing trends, such as hypertensive diseases.

导言:这项全国性研究旨在分析 2001 年至 2020 年期间希腊各种原因导致的死亡率趋势,重点关注受冠状病毒大流行影响的 2020 年。由于希腊是欧洲老龄化速度最快的国家,研究结果可用于指导全球卫生政策的重新评估:方法:从希腊统计局获取人口和死亡人数数据。我们计算了 2001 年至 2020 年三个年龄组(0-64 岁、65-79 岁和 80 岁以上)按性别划分的年龄标准化死亡率(ASMR)和特定原因死亡率。确定了 2020 年的比例死亡率。统计分析使用了 Python 编程语言的广义线性模型:结果:从 2001 年到 2020 年,心血管疾病(CVD)的 ASMR 下降了 42.7%(pConclusions):全球人口老龄化现象要求我们在老龄化社会中重新制定卫生政策,重点关注死亡率高的疾病(如心血管疾病、肿瘤和脊髓灰质炎)或呈上升趋势的疾病(如高血压疾病)。
{"title":"Nationwide mortality trends from 2001 to 2020 in Greece: health policy implications under the scope of aging societies.","authors":"Maria Nikolaou, Nikolaos Theodorakis, Georgios Feretzakis, Georgia Vamvakou, Christos Hitas, Sofia Kalantzi, Aikaterini Spyridaki, Anastasios Apostolos, Vassilios S Verykios, Konstantinos Toutouzas","doi":"10.1016/j.hjc.2024.08.009","DOIUrl":"10.1016/j.hjc.2024.08.009","url":null,"abstract":"<p><strong>Objective: </strong>This nationwide study aims to analyze mortality trends for all individual causes in Greece from 2001 to 2020, with a specific focus on 2020, a year influenced by the COVID-19 pandemic. As Greece is the fastest-aging country in Europe, the study's findings can be generalized to other aging societies, guiding the reevaluation of global health policies.</p><p><strong>Methods: </strong>Data on the population and the number of deaths were retrieved from the Hellenic Statistical Authority. We calculated age-standardized mortality rates (ASMR) and cause-specific mortality rates by sex in three age groups (0-64, 65-79, and 80+ years) from 2001 to 2020. Proportional mortality rates for 2020 were determined. Statistical analysis used generalized linear models with Python Programming Language.</p><p><strong>Results: </strong>From 2001 to 2020, the ASMR of cardiovascular diseases (CVD) decreased by 42.7% (p < 0.0001), with declines in most sub-causes, except for hypertensive diseases, which increased by 2.8-fold (p < 0.0001). In 2020, the proportional mortality rates of the three leading causes were 34.9% for CVD, 23.5% for neoplasms, and 9.6% for respiratory diseases (RD). In 2020, CVD were the leading cause of death among individuals aged 80+ years (39.3%), while neoplasms were the leading cause among those aged 0-79 years (37.7%). Among cardiovascular sub-causes, cerebrovascular diseases were predominant in the 80+ year age group (30.3%), while ischemic heart diseases were most prevalent among those aged 0-79 years (up to 60.0%).</p><p><strong>Conclusions: </strong>The global phenomenon of population aging necessitates a reframing of health policies in our aging societies, focusing on diseases with either a high mortality burden, such as CVD, neoplasms, and RD, or those experiencing increasing trends, such as hypertensive diseases.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renin-angiotensin system inhibitors and non-ST-elevation myocardial infarction outcomes based on left ventricular ejection fraction. 基于左心室射血分数的肾素-血管紧张素系统抑制剂与非ST段抬高型心肌梗死的预后。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-14 DOI: 10.1016/j.hjc.2024.08.007
Yong Hoon Kim, Ae-Young Her, Seung-Woon Rha, Cheol Ung Choi, Byoung Geol Choi, Soohyung Park, Dong Oh Kang, Se Yeon Choi, Jinah Cha, Su Jin Hyun, Jung Rae Cho, Min-Woong Kim, Ji Young Park, Sang-Ho Park, Myung Ho Jeong

Background: We assessed left ventricular ejection fraction (LVEF) to compare the effects of renin-angiotensin system inhibitors (RASI) in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

Methods: We categorized 4558 patients with NSTEMI as either RASI users (3752 patients) or non-users (806 patients). The 3-year patient-oriented composite outcome (POCO), which included all-cause death, recurrent myocardial infarction, any repeat revascularization, or hospitalization for heart failure (HF), was the primary outcome. To compare clinical outcomes, a multivariable-adjusted hazard ratio (aHR) was calculated after performing multicollinearity tests on all significant confounding variables (P < 0.05).

Results: Among RASI users, the aHRs for POCO, all-cause death, and cardiac death were significantly higher in the HF with reduced EF (HFrEF) subgroup than in the HF with mildly reduced EF (HFmrEF) (1.610, 2.120, and 2.489; P < 0.001, <0.001, and <0.001; respectively) and HF with preserved EF (HFpEF) (2.234, 3.920, and 5.215; P < 0.001, <0.001, and <0.001; respectively) subgroups. The aHRs for these variables were significantly higher in the HFmrEF subgroup than the HFpEF subgroup (1.416, 1.843, and 2.172, respectively). Among RASI non-users, the aHRs for these variables were significantly higher in the HFrEF subgroup than the HFmrEF (2.573, 3.172, and 3.762, respectively) and HFpEF (2.425, 3.805, and 4.178, respectively) subgroups. In three LVEF subgroups, RASI users exhibited lower aHRs for POCO and all-cause death than RASI non-users.

Conclusion: In the RASI users group, the aHRs for POCO and mortality were highest in the HFrEF subgroup, intermediate in the HFmrEF subgroup, and lowest in the HFpEF subgroup.

背景:我们评估了左心室射血分数(LVEF),以比较肾素-血管紧张素系统抑制剂(RASI)对非ST段抬高型心肌梗死(NSTEMI)患者的影响:我们将 4558 例 NSTEMI 患者分为 RASI 使用者(3752 例)和非使用者(806 例)。3年以患者为导向的综合结果(POCO)是主要结果,包括全因死亡、复发性心肌梗死、任何重复血管再通或因心衰(HF)住院。为了比较临床结果,在对所有重要混杂变量进行多重共线性测试后,计算了经多变量调整的危险比(aHR)(P在 RASI 用户组中,HFrEF 亚组的 POCO 和死亡率 aHR 最高,HFmrEF 亚组居中,HFpEF 亚组最低。
{"title":"Renin-angiotensin system inhibitors and non-ST-elevation myocardial infarction outcomes based on left ventricular ejection fraction.","authors":"Yong Hoon Kim, Ae-Young Her, Seung-Woon Rha, Cheol Ung Choi, Byoung Geol Choi, Soohyung Park, Dong Oh Kang, Se Yeon Choi, Jinah Cha, Su Jin Hyun, Jung Rae Cho, Min-Woong Kim, Ji Young Park, Sang-Ho Park, Myung Ho Jeong","doi":"10.1016/j.hjc.2024.08.007","DOIUrl":"10.1016/j.hjc.2024.08.007","url":null,"abstract":"<p><strong>Background: </strong>We assessed left ventricular ejection fraction (LVEF) to compare the effects of renin-angiotensin system inhibitors (RASI) in patients with non-ST-segment elevation myocardial infarction (NSTEMI).</p><p><strong>Methods: </strong>We categorized 4558 patients with NSTEMI as either RASI users (3752 patients) or non-users (806 patients). The 3-year patient-oriented composite outcome (POCO), which included all-cause death, recurrent myocardial infarction, any repeat revascularization, or hospitalization for heart failure (HF), was the primary outcome. To compare clinical outcomes, a multivariable-adjusted hazard ratio (aHR) was calculated after performing multicollinearity tests on all significant confounding variables (P < 0.05).</p><p><strong>Results: </strong>Among RASI users, the aHRs for POCO, all-cause death, and cardiac death were significantly higher in the HF with reduced EF (HFrEF) subgroup than in the HF with mildly reduced EF (HFmrEF) (1.610, 2.120, and 2.489; P < 0.001, <0.001, and <0.001; respectively) and HF with preserved EF (HFpEF) (2.234, 3.920, and 5.215; P < 0.001, <0.001, and <0.001; respectively) subgroups. The aHRs for these variables were significantly higher in the HFmrEF subgroup than the HFpEF subgroup (1.416, 1.843, and 2.172, respectively). Among RASI non-users, the aHRs for these variables were significantly higher in the HFrEF subgroup than the HFmrEF (2.573, 3.172, and 3.762, respectively) and HFpEF (2.425, 3.805, and 4.178, respectively) subgroups. In three LVEF subgroups, RASI users exhibited lower aHRs for POCO and all-cause death than RASI non-users.</p><p><strong>Conclusion: </strong>In the RASI users group, the aHRs for POCO and mortality were highest in the HFrEF subgroup, intermediate in the HFmrEF subgroup, and lowest in the HFpEF subgroup.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Better performance of the APPLE score for the prediction of very early atrial fibrillation recurrence post-ablation. APPLE 评分在预测消融术后早期房颤复发方面表现更佳。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-13 DOI: 10.1016/j.hjc.2024.08.008
Wenchao Huang, Huaxin Sun, Yan Luo, Shiqiang Xiong, Yan Tang, Yu Long, Zhen Zhang, Hanxiong Liu

Objective: The benefits of rhythm control in early atrial fibrillation (AF) are increasingly recognized. This study aimed to investigate whether early AF ablation contributes to long-term sinus rhythm maintenance and to identify a suitable predictive score.

Methods: According to diagnosis-to-ablation time, this study prospectively enrolled 245 patients with very early AF, 262 with early AF, and 588 with late AF for radiofrequency ablation from June 2017 to December 2022. Clinical data, risk scores, and follow-up results were collected and analyzed.

Results: Baseline characteristics were similar among the three cohorts. During a median follow-up period of 26 months, AF recurrence was observed in 61 (24.9%), 66 (25.2%), and 216 (36.7%) patients in the very early, early, and late AF cohorts, respectively. In the multivariable-adjusted model, very early and early AF were associated with a reduced risk of AF recurrence, with hazard ratios of 0.72 (95% confidence interval [CI] 0.52-0.99) and 0.57 (95% CI 0.41-0.78), respectively. The APPLE score demonstrated the highest predictive power for very early AF, with an area under the curve (AUC) of 0.74. However, its predictive power decreased with time from diagnosis, showing low predictive power for late AF (AUC = 0.58). In addition, the time-dependent concordance index showed consistent results. For very early AF, the Akaike information criterion and decision curve analysis showed that APPLE had the highest predictive value.

Conclusion: Very early AF ablation was associated with a lower recurrence rate, and the APPLE score provided a higher predictive value for these patients. (URL: https://www.chictr.org.cn/; Unique identifier: ChiCTR-OIN-17013021).

背景:越来越多的人认识到早期房颤(AF)节律控制的益处。本研究旨在探讨早期房颤消融是否有助于窦性心律的长期维持,并确定合适的预测评分:根据从诊断到消融的时间,本研究在2017年6月至2022年12月期间前瞻性地招募了245名极早期房颤患者、262名早期房颤患者和588名晚期房颤患者进行射频消融。收集并分析了临床数据、风险评分和随访结果:三组患者的基线特征相似。中位随访期为26个月,在极早期、早期和晚期房颤组别中,分别有61例(24.9%)、66例(25.2%)和216例(36.7%)患者观察到房颤复发。在多变量调整模型中,极早期和早期房颤与房颤复发风险降低相关,危险比分别为 0.72(95% 置信区间 [CI]:0.52-0.99)和 0.57(95% CI:0.41-0.78)。APPLE 评分对极早期房颤的预测能力最高,曲线下面积 (AUC) 为 0.74。然而,其预测能力随着诊断时间的延长而下降,对晚期房颤的预测能力较低(AUC=0.58)。此外,与时间相关的一致性指数也显示出一致的结果。对于极早期房颤,阿凯克信息标准和决策曲线分析表明,APPLE的预测价值最高:结论:极早期房颤消融与较低的复发率相关,APPLE 评分可为其提供较高的预测值。(网址:https://www.chictr.org.cn/;唯一标识符:ChiCTR-OIN-17013021)。
{"title":"Better performance of the APPLE score for the prediction of very early atrial fibrillation recurrence post-ablation.","authors":"Wenchao Huang, Huaxin Sun, Yan Luo, Shiqiang Xiong, Yan Tang, Yu Long, Zhen Zhang, Hanxiong Liu","doi":"10.1016/j.hjc.2024.08.008","DOIUrl":"10.1016/j.hjc.2024.08.008","url":null,"abstract":"<p><strong>Objective: </strong>The benefits of rhythm control in early atrial fibrillation (AF) are increasingly recognized. This study aimed to investigate whether early AF ablation contributes to long-term sinus rhythm maintenance and to identify a suitable predictive score.</p><p><strong>Methods: </strong>According to diagnosis-to-ablation time, this study prospectively enrolled 245 patients with very early AF, 262 with early AF, and 588 with late AF for radiofrequency ablation from June 2017 to December 2022. Clinical data, risk scores, and follow-up results were collected and analyzed.</p><p><strong>Results: </strong>Baseline characteristics were similar among the three cohorts. During a median follow-up period of 26 months, AF recurrence was observed in 61 (24.9%), 66 (25.2%), and 216 (36.7%) patients in the very early, early, and late AF cohorts, respectively. In the multivariable-adjusted model, very early and early AF were associated with a reduced risk of AF recurrence, with hazard ratios of 0.72 (95% confidence interval [CI] 0.52-0.99) and 0.57 (95% CI 0.41-0.78), respectively. The APPLE score demonstrated the highest predictive power for very early AF, with an area under the curve (AUC) of 0.74. However, its predictive power decreased with time from diagnosis, showing low predictive power for late AF (AUC = 0.58). In addition, the time-dependent concordance index showed consistent results. For very early AF, the Akaike information criterion and decision curve analysis showed that APPLE had the highest predictive value.</p><p><strong>Conclusion: </strong>Very early AF ablation was associated with a lower recurrence rate, and the APPLE score provided a higher predictive value for these patients. (URL: https://www.chictr.org.cn/; Unique identifier: ChiCTR-OIN-17013021).</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hellenic Journal of Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1